Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DECREASE
NCT04166318Phase 2Active, not recruiting
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Jan 2020
- Primary completion
- Dec 2029
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fluorouracil, capecitabine, mitomycin c in anal squamous cell carcinoma (SCCA), sponsored by ECOG-ACRIN Cancer Research Group. Started Jan 2020; status: active, not recruiting.
02
Drugs
fluorouracilcapecitabinemitomycin c
03
Conditions
anal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on NCT04166318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04166318.